This article is more than 5 years old. Information may no longer be current.

FDA approves next-generation Boston Scientific ICDs, CRT-Ds

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Boston Scientific announced that it has received FDA approval for its newest generation of implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators.

The devices covered in the approval include the Dynagen Mini and Inogen Mini ICDs and the Dynagen X4 and Inogen X4 CRT-Ds. The Mini ICDs are up to 20% smaller and 24% thinner than other available ICDs, according to a company press release.

The X4 line of quadripolar CRT-Ds offers a large battery capacity and 70% more pacing options to address high capture thresholds and phrenic nerve stimulation effectively, according to the release.

The devices are indicated for patients with HF and/or patients at high risk for sudden cardiac death.